The crystal structure of the inclusion complex of the sodium salt of piroxicam with β-cyclodextrin

被引:7
作者
Chiesi-Villa, A
Rizzoli, C
Amari, G
Delcanale, M
Redenti, E
Ventura, P
机构
[1] Univ Parma, Dipartimento Chim Inorgan Chim Analit & Chim Fis, I-43100 Parma, Italy
[2] Chiesi Farmaceutici SpA, Chem & Biopharmaceut Dept, I-43100 Parma, Italy
关键词
beta-cyclodextrin; piroxicam; drug; solid state structure; inclusion;
D O I
10.1080/10610279808055402
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The structural characterization by X-ray diffraction analysis of the title compound is reported. Crystallographic details are: C42H70O35. C15H12N3O4 SNa . 8D(2)O, triclinic, space group pi, a=14.767(3), b = 12.237(2), c=11.537(2) Angstrom, alpha = 79.49(1), beta = 110.91-(1), c=104.61(1)degrees, d(calc)=1.460g/cm(3) Z=1, R=0.045 for 6635 observed reflections. The crystal structure consists of head-to-tail beta-cyclodextrin molecules (beta-CD) linked together by piroxicam anions in infinite polymeric chains running along the c axis. In a chain each beta-CD molecule takes up simultaneously two guest molecules including on the secondary hydroxyl end the benzene ring and on the primary hydroxyl end the pyridine ring of two adjacent piroxicam anions. The piroxicam anion is located with its central hydrophilic moiety at the interface between two adjacent beta-CD molecules, forming with them hydrogen bonds through the enolate and amide oxygen atoms. Conformation of piroxicam is different from those observed for its neutral and zwitterionic forms. It assumes the ZZE conformation expected for the enolate. The six-coordinated sodium cation acts as a bridge between adjacent polymeric chains linking them along the b axis. This results in the formation of hydrophilic channels filled by deuterium oxide molecules.
引用
收藏
页码:111 / 119
页数:9
相关论文
共 18 条
[1]  
ACERBI D, 1990, DRUG INVEST S4, V2, P29
[2]  
ALTOMARE A, 1994, J APPL CRYSTALLOGR, V27, P635
[3]  
[Anonymous], J INCL PHENOM
[4]  
[Anonymous], INT TABLES XRAY CRYS
[5]   DEUTERIUM-ISOTOPE EFFECTS ON C-13 NMR SHIFTS AND THE TAUTOMERIC EQUILIBRIUM IN N-SUBSTITUTED PYRIDYL DERIVATIVES OF PIROXICAM [J].
BORDNER, J ;
HAMMEN, PD ;
WHIPPLE, EB .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1989, 111 (17) :6572-6578
[6]   PIROXICAM MONOHYDRATE - A ZWITTERIONIC FORM, C15H13N3O4S.H2O [J].
BORDNER, J ;
RICHARDS, JA ;
WEEKS, P ;
WHIPPLE, EB .
ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS, 1984, 40 (JUN) :989-990
[7]   Synthesis, crystal structure and molecular orbital investigation of the first platinum complex of piroxicam [J].
Cini, R .
JOURNAL OF THE CHEMICAL SOCIETY-DALTON TRANSACTIONS, 1996, (01) :111-116
[8]   METAL-COMPLEXES OF THE ANTIINFLAMMATORY DRUG PIROXICAM [J].
CINI, R ;
GIORGI, G ;
CINQUANTINI, A ;
ROSSI, C ;
SABAT, M .
INORGANIC CHEMISTRY, 1990, 29 (26) :5197-5200
[9]   PROTON NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY STUDIES OF THE INCLUSION COMPLEX OF PIROXICAM WITH BETA-CYCLODEXTRIN [J].
FRONZA, G ;
MELE, A ;
REDENTI, E ;
VENTURA, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (12) :1162-1165
[10]   CRYSTAL-STRUCTURES OF INCLUSION COMPLEXES OF BETA-CYCLODEXTRIN WITH (S)-(+)-FENOPROFEN AND (R)-(-)-FENOPROFEN [J].
HAMILTON, JA ;
CHEN, LY .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1988, 110 (13) :4379-4391